Page last updated: 2024-12-11
crotarbital
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
crotarbital: RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5364821 |
SCHEMBL ID | 712976 |
SCHEMBL ID | 2285746 |
MeSH ID | M0040687 |
Synonyms (48)
Synonym |
---|
ethyl(crotyl)barbiturate |
nsc125735 |
ethyl-crotyl-barbiturate |
kalipnon |
nsc-125735 |
mepertan |
barbituric acid, 5-(2-butenyl)-5-ethyl- |
crotarbital |
barotal |
go 1046 |
2,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl- |
calypnone |
barotalum |
kalypnetten |
1952-67-6 |
5-(2-butenyl)-5-ethylbarbituric acid |
5-ethyl-5-crotylbarbituric acid |
kalypnon |
crotylbarbital |
crotylbarbitalum |
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl- |
einecs 217-777-9 |
nsc 125735 |
ethyl (crotyl)barbiturate |
5-(2-butenyl)-5-ethyl-1h,3h,5h-pyrimidine-2,4,6-trione |
5-aethyl-5-crotylbarbitursaure [german] |
5-[(e)-but-2-enyl]-5-ethyl-1,3-diazinane-2,4,6-trione |
5-aethyl-5-crotylbarbitursaure |
unii-sxw2hl5ju7 |
sxw2hl5ju7 , |
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-butenyl)-5-ethyl-, (e)- |
crotarbital [who-dd] |
crotylbarbitone |
28360-89-6 |
5-crotyl-5-ethylbarbituric acid |
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-buten-1-yl)-5-ethyl- |
crotarbitone |
go-1046 |
crotylbital |
SCHEMBL712976 |
KNMOHCLEINXVBG-HWKANZROSA-N |
5-[2-butenyl]-5-ethyl-2,4,6(1h,3h,5h)-pyrimidinetrione # |
SCHEMBL2285746 |
HY-101629 |
CS-6573 |
(e)-crotylbarbital |
Q5189013 |
AKOS040732215 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 7 (87.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (10.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |